At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Apr 3, 2026 at 16:01 ET
Spyre Therapeutics granted stock options to purchase 70,200 shares to five non-executive employees as inducement awards under its 2018 Equity Inducement Plan. The options have a 10-year term, an exercise price of $48.90, and vest over four years, with one-fourth vesting on the first anniversary and monthly thereafter, subject to continued service.
- Spyre granted stock options for 70,200 shares to five non-executive employees.
- Options were granted under Nasdaq Listing Rule 5635(c)(4) as inducement awards.
- Exercise price is $48.90, equal to the closing price on April 1, 2026.
- Options have a 10-year term and vest 25% on first anniversary, then 1/48th monthly over next 36 months.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access